Vigil Neuroscience (NASDAQ:VIGL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a report published on Friday morning, Benzinga reports. The firm currently has a $24.00 price target on the stock.

Other research analysts have also recently issued research reports about the stock. Wedbush restated an outperform rating and set a $22.00 target price on shares of Vigil Neuroscience in a report on Wednesday, May 8th. JMP Securities restated a market outperform rating and set a $23.00 target price on shares of Vigil Neuroscience in a report on Thursday, April 18th.

Vigil Neuroscience Trading Down 10.7 %

Vigil Neuroscience stock opened at $4.00 on Friday. Vigil Neuroscience has a twelve month low of $2.47 and a twelve month high of $10.22. The company has a 50 day moving average of $3.51 and a 200-day moving average of $3.32.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.10. As a group, analysts anticipate that Vigil Neuroscience will post -2.09 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in VIGL. Vanguard Group Inc. raised its position in Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after acquiring an additional 95,276 shares in the last quarter. PEAK6 Investments LLC raised its position in Vigil Neuroscience by 66.0% during the third quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock worth $128,000 after acquiring an additional 9,459 shares in the last quarter. Finally, Strs Ohio bought a new stake in Vigil Neuroscience during the fourth quarter worth $27,000. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.